Keyword: Taltz

Drugmakers used last weekend’s American Association of Dermatology annual meeting to trumpet new psoriasis data they hoped would give them an edge.

Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.

What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis.

Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.

A couple of drugmakers are celebrating this week after favorable decisions from England’s cost watchdog.

China's inviting top brands from Lilly, Novartis, GSK and more to go for approval based on foreign clinical trial data.

Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara.

Roche sued Lilly Tuesday, claiming the two-year-old psoriasis med Taltz steps on one of its patents. Thing is, Roche just won that patent this week.

With some new data in hand, Eli Lilly's Taltz looks poised to challenge Novartis' Cosentyx in a third indication.

As the psoriatic arthritis field heats up, Novartis has added some new data to its Cosentyx label it hopes can stretch out the drug’s lead.